Search | Clinical Trials Finder

Conditions: Obesity
Interventions: Administration of weight loss drug (Metformin or Topiramate); Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Preeclampsia Severe, Pre-Eclampsia, Preeclampsia, Preeclampsia Second Trimester, Preeclampsia Complicating Childbirth, Preeclampsia Puerperium, Preterm
Interventions: Metformin, Esomeprazole; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions: metformin hydrochloride, placebo, Chemotherapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: Metformin, Dietary modification with caloric restriction, Establishment of exercise protocol; Drug · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus Type 2
Interventions: DPP-IV Inhibitor, Metformin, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Concord, California • Salinas, California • San Diego, California + 17 more

Conditions: Healthy
Interventions: Metformin HCl; Drug
Lead sponsor: Torrent Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Metformin, saxagliptin, AZD9668, placebo; Drug
Lead sponsor: Nick Giannoukakis, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
Interventions: Metformin; Drug
Lead sponsor: Woodinville Psychiatric Associates; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Woodinville, Washington

Conditions: Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions: Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High; Drug
Lead sponsor: ARKAY Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Albany, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Insulin Resistance, Postmenopause
Interventions: metformin, leuprolide injection, placebo pill, placebo injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years to 79 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Glimepiride; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Subjects
Interventions: Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID); Drug
Lead sponsor: Cortendo AB; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders
Interventions: Placebo Medication, Metformin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Years to 25 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Fanconi Anemia
Interventions: metformin HCl; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions: Byetta 5Mcg Pen Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperglycemia
Interventions: Metformin, Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Recurrent Endometrial Carcinoma
Interventions: Metformin use; Drug
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 39
States / cities: Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Glucovance (metformin HCl/glyburide), metformin HCl, glyburide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 9 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more

Conditions: Healthy
Interventions: Glipizide and Metformin HCl Tablets 5 mg/500 mg, Metaglip® Tablets 5 mg/500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Diabetes Mellitus Type 2
Interventions: aleglitazar+metformin, placebo+metformin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 22
States / cities: Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more

Search by objective public record fields.

Efficacy of Pharmacotherapy to Enhance Weight Loss Following Sleeve Gastrectomy

Metformin and Esomeprazole in Preterm Pre-eclampsia

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Heart Rate Variability in Response to Metformin Challenge

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Insulin Resistance and Testosterone in Women

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

Drug Interaction Study of Levoketoconazole and Metformin

A Trial of Metformin in Individuals With Fragile X Syndrome

Pilot Study of Metformin for Patients With Fanconi Anemia

Liver and Fat Regulation in Overweight Adolescent Girls

Metformin Use in Patients Undergoing Total Joint Replacement Surgery

Endometrial Cancer Recurrence in Patients Taking Metformin

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone